Cutaneous Lupus Erythematosus – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of cutaneous lupus erythematosus (CLE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of CLE for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the mature pharmaceutical markets of the United States, Europe, and Japan.
Clarivate Epidemiology’s CLE forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of CLE?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CLE over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following CLE populations:
- Diagnosed prevalent cases of CLE.
- Diagnosed incident cases of CLE.
- Diagnosed prevalent cases of CLE by severity.
Note: Coverage may vary by country.
